Scott Auerbach
Concepts (391)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 41 | 2026 | 680 | 7.560 |
Why?
| | Heart-Assist Devices | 22 | 2026 | 568 | 3.830 |
Why?
| | Heart Failure | 27 | 2026 | 2326 | 2.760 |
Why?
| | Graft Rejection | 13 | 2025 | 521 | 2.070 |
Why?
| | Graft Survival | 11 | 2025 | 519 | 1.970 |
Why?
| | Gene Expression Profiling | 11 | 2025 | 1777 | 1.150 |
Why?
| | Toxicity Tests | 7 | 2025 | 53 | 1.150 |
Why?
| | Heart Defects, Congenital | 12 | 2026 | 910 | 1.120 |
Why?
| | Transcriptome | 12 | 2025 | 1042 | 1.110 |
Why?
| | Muscular Dystrophy, Duchenne | 5 | 2025 | 93 | 1.100 |
Why?
| | Cardiomyopathies | 10 | 2025 | 335 | 1.070 |
Why?
| | Child | 59 | 2026 | 22740 | 1.060 |
Why?
| | Heart Diseases | 3 | 2023 | 341 | 0.990 |
Why?
| | Mutagens | 6 | 2025 | 27 | 0.990 |
Why?
| | Glomerular Filtration Rate | 3 | 2026 | 765 | 0.980 |
Why?
| | Liver | 9 | 2025 | 1899 | 0.970 |
Why?
| | Toxicogenetics | 5 | 2023 | 6 | 0.840 |
Why?
| | Carcinogens | 5 | 2025 | 123 | 0.810 |
Why?
| | Steroids | 2 | 2015 | 160 | 0.790 |
Why?
| | Myocarditis | 2 | 2023 | 102 | 0.770 |
Why?
| | Child, Preschool | 29 | 2026 | 11868 | 0.760 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 668 | 0.680 |
Why?
| | Immunosuppressive Agents | 5 | 2025 | 838 | 0.670 |
Why?
| | Kidney Transplantation | 3 | 2026 | 712 | 0.660 |
Why?
| | Adolescent | 39 | 2026 | 22577 | 0.650 |
Why?
| | Toxicology | 4 | 2025 | 49 | 0.650 |
Why?
| | Environmental Pollutants | 4 | 2025 | 139 | 0.630 |
Why?
| | Registries | 15 | 2025 | 2410 | 0.620 |
Why?
| | Humans | 99 | 2026 | 145783 | 0.600 |
Why?
| | Organ Transplantation | 4 | 2024 | 253 | 0.600 |
Why?
| | Liver Neoplasms, Experimental | 2 | 2018 | 26 | 0.580 |
Why?
| | Small Molecule Libraries | 2 | 2017 | 111 | 0.570 |
Why?
| | Benchmarking | 6 | 2024 | 191 | 0.570 |
Why?
| | Retrospective Studies | 25 | 2026 | 17330 | 0.540 |
Why?
| | Infant | 23 | 2026 | 10091 | 0.540 |
Why?
| | Treatment Outcome | 20 | 2025 | 11794 | 0.520 |
Why?
| | Plant Preparations | 3 | 2025 | 37 | 0.520 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 599 | 0.520 |
Why?
| | Exome | 1 | 2018 | 229 | 0.510 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 394 | 0.500 |
Why?
| | Male | 49 | 2026 | 73011 | 0.490 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 750 | 0.490 |
Why?
| | Prosthesis-Related Infections | 1 | 2017 | 98 | 0.490 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 534 | 0.480 |
Why?
| | Disease Management | 1 | 2020 | 653 | 0.470 |
Why?
| | Cardiomyopathy, Dilated | 4 | 2022 | 356 | 0.460 |
Why?
| | Risk Factors | 16 | 2026 | 10919 | 0.450 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 778 | 0.450 |
Why?
| | Extracorporeal Membrane Oxygenation | 4 | 2022 | 390 | 0.440 |
Why?
| | Follow-Up Studies | 10 | 2025 | 5428 | 0.430 |
Why?
| | Cardiology | 1 | 2017 | 362 | 0.420 |
Why?
| | Stroke | 1 | 2023 | 1271 | 0.410 |
Why?
| | Young Adult | 14 | 2024 | 14254 | 0.400 |
Why?
| | Myocardium | 3 | 2022 | 935 | 0.390 |
Why?
| | High-Throughput Screening Assays | 5 | 2020 | 177 | 0.390 |
Why?
| | Female | 38 | 2026 | 79045 | 0.390 |
Why?
| | Risk Assessment | 8 | 2025 | 3752 | 0.380 |
Why?
| | Sequence Analysis, RNA | 2 | 2014 | 442 | 0.380 |
Why?
| | DNA Damage | 6 | 2025 | 437 | 0.360 |
Why?
| | Histones | 1 | 2017 | 666 | 0.340 |
Why?
| | Biomarkers | 9 | 2025 | 4302 | 0.330 |
Why?
| | Postoperative Complications | 6 | 2025 | 2977 | 0.320 |
Why?
| | Echocardiography | 3 | 2022 | 648 | 0.320 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2601 | 0.320 |
Why?
| | Delivery of Health Care | 1 | 2017 | 948 | 0.320 |
Why?
| | Mutation | 2 | 2019 | 4090 | 0.320 |
Why?
| | Dietary Supplements | 3 | 2019 | 584 | 0.320 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 109 | 0.300 |
Why?
| | Metabolomics | 4 | 2024 | 733 | 0.300 |
Why?
| | Waiting Lists | 4 | 2024 | 266 | 0.300 |
Why?
| | Computational Biology | 4 | 2025 | 669 | 0.290 |
Why?
| | Cimicifuga | 2 | 2019 | 2 | 0.290 |
Why?
| | Transforming Growth Factor alpha | 1 | 2009 | 55 | 0.290 |
Why?
| | Transplant Recipients | 4 | 2024 | 182 | 0.280 |
Why?
| | Mutagenicity Tests | 4 | 2025 | 18 | 0.280 |
Why?
| | Databases, Factual | 5 | 2024 | 1491 | 0.270 |
Why?
| | Everolimus | 2 | 2025 | 112 | 0.270 |
Why?
| | Models, Theoretical | 2 | 2023 | 560 | 0.260 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 119 | 0.260 |
Why?
| | Genomics | 4 | 2023 | 830 | 0.250 |
Why?
| | Tacrolimus | 2 | 2025 | 196 | 0.250 |
Why?
| | Computer Simulation | 4 | 2021 | 1003 | 0.250 |
Why?
| | Infant, Newborn | 11 | 2025 | 6465 | 0.240 |
Why?
| | Plant Extracts | 2 | 2018 | 188 | 0.240 |
Why?
| | Formaldehyde | 2 | 2018 | 65 | 0.240 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 474 | 0.240 |
Why?
| | Rats | 10 | 2025 | 5585 | 0.240 |
Why?
| | Ventricular Function, Left | 3 | 2022 | 544 | 0.240 |
Why?
| | Animals | 24 | 2025 | 38102 | 0.230 |
Why?
| | Survival Rate | 4 | 2025 | 2094 | 0.230 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2025 | 2028 | 0.230 |
Why?
| | Incidence | 4 | 2025 | 2934 | 0.220 |
Why?
| | Alkanesulfonic Acids | 1 | 2025 | 35 | 0.220 |
Why?
| | Interleukin-6 | 1 | 2009 | 780 | 0.220 |
Why?
| | Time Factors | 6 | 2025 | 7134 | 0.210 |
Why?
| | Stroke Volume | 4 | 2022 | 655 | 0.210 |
Why?
| | Biotransformation | 1 | 2024 | 62 | 0.210 |
Why?
| | Aflatoxin B1 | 2 | 2014 | 2 | 0.210 |
Why?
| | DNA | 2 | 2019 | 1437 | 0.210 |
Why?
| | Kidney | 2 | 2023 | 1497 | 0.210 |
Why?
| | Animal Testing Alternatives | 2 | 2021 | 3 | 0.200 |
Why?
| | Automobile Driving | 1 | 2026 | 157 | 0.200 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1547 | 0.200 |
Why?
| | Adverse Outcome Pathways | 1 | 2023 | 3 | 0.200 |
Why?
| | Fluorocarbons | 1 | 2025 | 120 | 0.200 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1330 | 0.190 |
Why?
| | Consensus | 2 | 2025 | 479 | 0.190 |
Why?
| | Vasoplegia | 1 | 2022 | 5 | 0.190 |
Why?
| | Heart Injuries | 1 | 2023 | 42 | 0.190 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 129 | 0.190 |
Why?
| | Muscular Dystrophies | 1 | 2022 | 28 | 0.180 |
Why?
| | Hep G2 Cells | 2 | 2025 | 73 | 0.180 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 171 | 0.180 |
Why?
| | Rodentia | 1 | 2022 | 61 | 0.180 |
Why?
| | American Heart Association | 2 | 2021 | 358 | 0.180 |
Why?
| | Ginkgo biloba | 2 | 2018 | 10 | 0.170 |
Why?
| | Organisation for Economic Co-Operation and Development | 1 | 2021 | 2 | 0.170 |
Why?
| | Adult | 12 | 2024 | 40881 | 0.170 |
Why?
| | Structure-Activity Relationship | 3 | 2017 | 563 | 0.170 |
Why?
| | Hepatocytes | 2 | 2019 | 224 | 0.170 |
Why?
| | Databases, Chemical | 2 | 2019 | 9 | 0.170 |
Why?
| | Clinical Protocols | 1 | 2022 | 280 | 0.170 |
Why?
| | Pesticides | 1 | 2021 | 59 | 0.170 |
Why?
| | Coronary Vessels | 2 | 2021 | 246 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1372 | 0.160 |
Why?
| | Echinacea | 1 | 2019 | 2 | 0.150 |
Why?
| | Age Factors | 4 | 2021 | 3346 | 0.150 |
Why?
| | Adjustment Disorders | 1 | 2019 | 5 | 0.150 |
Why?
| | Quantitative Structure-Activity Relationship | 2 | 2017 | 18 | 0.150 |
Why?
| | Arsenites | 1 | 2019 | 6 | 0.150 |
Why?
| | Stents | 1 | 2023 | 564 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 40 | 0.150 |
Why?
| | Cohort Studies | 5 | 2024 | 6033 | 0.150 |
Why?
| | Logistic Models | 1 | 2024 | 2139 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 971 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 337 | 0.140 |
Why?
| | Food Contamination | 1 | 2018 | 33 | 0.140 |
Why?
| | Gene Amplification | 1 | 2019 | 118 | 0.140 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 69 | 0.140 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 166 | 0.140 |
Why?
| | Liver Transplantation | 1 | 2026 | 827 | 0.140 |
Why?
| | United States | 9 | 2022 | 16126 | 0.140 |
Why?
| | Eugenol | 1 | 2018 | 4 | 0.140 |
Why?
| | Tissue Fixation | 1 | 2018 | 37 | 0.140 |
Why?
| | Ultrasonography | 2 | 2020 | 788 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2021 | 192 | 0.140 |
Why?
| | Paraffin Embedding | 1 | 2018 | 33 | 0.140 |
Why?
| | Coronary Angiography | 1 | 2020 | 328 | 0.140 |
Why?
| | Prostate | 1 | 2019 | 159 | 0.130 |
Why?
| | HEK293 Cells | 2 | 2018 | 741 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 254 | 0.130 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 160 | 0.130 |
Why?
| | Mice, Inbred Strains | 1 | 2018 | 396 | 0.130 |
Why?
| | Isoantibodies | 1 | 2017 | 57 | 0.130 |
Why?
| | Cryopreservation | 1 | 2018 | 113 | 0.130 |
Why?
| | Cell Culture Techniques | 2 | 2017 | 375 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 403 | 0.130 |
Why?
| | Uniparental Disomy | 1 | 2017 | 9 | 0.130 |
Why?
| | Gene Expression | 2 | 2019 | 1478 | 0.130 |
Why?
| | Research Design | 2 | 2023 | 1139 | 0.120 |
Why?
| | Anesthesia, Dental | 1 | 2017 | 21 | 0.120 |
Why?
| | Donor Selection | 1 | 2017 | 79 | 0.120 |
Why?
| | Epigenomics | 1 | 2017 | 117 | 0.120 |
Why?
| | Tooth Extraction | 1 | 2017 | 28 | 0.120 |
Why?
| | Muscular Diseases | 1 | 2017 | 109 | 0.120 |
Why?
| | Arsenic | 1 | 2017 | 65 | 0.120 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 37 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2968 | 0.120 |
Why?
| | Patient Selection | 1 | 2021 | 739 | 0.120 |
Why?
| | Depressive Disorder | 1 | 2019 | 374 | 0.120 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 134 | 0.120 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3418 | 0.120 |
Why?
| | Artificial Intelligence | 1 | 2021 | 381 | 0.120 |
Why?
| | DNA Repair | 2 | 2019 | 255 | 0.120 |
Why?
| | Models, Chemical | 1 | 2017 | 250 | 0.120 |
Why?
| | HLA Antigens | 1 | 2017 | 240 | 0.120 |
Why?
| | Systems Biology | 1 | 2016 | 68 | 0.120 |
Why?
| | Trisomy | 1 | 2017 | 78 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1512 | 0.120 |
Why?
| | Anesthesia, General | 1 | 2017 | 121 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2017 | 501 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2018 | 751 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 280 | 0.110 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2017 | 138 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2020 | 532 | 0.110 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 413 | 0.110 |
Why?
| | Neuromuscular Diseases | 1 | 2017 | 145 | 0.110 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 180 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 171 | 0.110 |
Why?
| | Heme Oxygenase-1 | 1 | 2015 | 76 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 404 | 0.110 |
Why?
| | Equipment Failure | 1 | 2015 | 115 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2024 | 2805 | 0.110 |
Why?
| | Biomarkers, Pharmacological | 1 | 2014 | 26 | 0.110 |
Why?
| | Aromatase Inhibitors | 1 | 2015 | 81 | 0.110 |
Why?
| | Perioperative Care | 1 | 2017 | 231 | 0.110 |
Why?
| | Freezing | 1 | 2014 | 83 | 0.110 |
Why?
| | Vaccination | 4 | 2024 | 1428 | 0.100 |
Why?
| | Rats, Inbred F344 | 1 | 2014 | 268 | 0.100 |
Why?
| | Cell Survival | 1 | 2017 | 1104 | 0.100 |
Why?
| | Crohn Disease | 1 | 2017 | 260 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1752 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 558 | 0.100 |
Why?
| | Cell Membrane | 1 | 2017 | 709 | 0.100 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 26 | 0.100 |
Why?
| | Dexmedetomidine | 1 | 2013 | 47 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 782 | 0.090 |
Why?
| | Propensity Score | 1 | 2015 | 377 | 0.090 |
Why?
| | Proteome | 1 | 2017 | 513 | 0.090 |
Why?
| | Epithelial Cells | 1 | 2019 | 1134 | 0.090 |
Why?
| | Hemodynamics | 2 | 2018 | 1118 | 0.090 |
Why?
| | Disease Progression | 1 | 2020 | 2865 | 0.090 |
Why?
| | Genetic Diseases, Inborn | 1 | 2012 | 45 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1296 | 0.090 |
Why?
| | Heart | 2 | 2022 | 626 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1122 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 527 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 327 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1043 | 0.080 |
Why?
| | Hospitalization | 1 | 2022 | 2461 | 0.080 |
Why?
| | Mental Disorders | 1 | 2020 | 1171 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2015 | 426 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 883 | 0.080 |
Why?
| | Antibody Formation | 2 | 2022 | 288 | 0.080 |
Why?
| | Recovery of Function | 1 | 2015 | 716 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2017 | 1360 | 0.080 |
Why?
| | Propanolamines | 1 | 2010 | 40 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 736 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 53 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1125 | 0.080 |
Why?
| | Prognosis | 3 | 2018 | 4330 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2514 | 0.070 |
Why?
| | Signal Transduction | 3 | 2018 | 5224 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2123 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2014 | 2000 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 428 | 0.070 |
Why?
| | Carcinogenicity Tests | 2 | 2022 | 13 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 528 | 0.070 |
Why?
| | Prospective Studies | 5 | 2026 | 8078 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6085 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 252 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 674 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 686 | 0.070 |
Why?
| | Survival Analysis | 1 | 2011 | 1378 | 0.070 |
Why?
| | RNA | 1 | 2014 | 912 | 0.070 |
Why?
| | Biological Assay | 2 | 2018 | 132 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 419 | 0.070 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2007 | 15 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 80 | 0.060 |
Why?
| | Genotype | 2 | 2009 | 1857 | 0.060 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2019 | 60 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 2525 | 0.060 |
Why?
| | Neoplasms | 1 | 2022 | 2913 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1043 | 0.060 |
Why?
| | Hemofiltration | 1 | 2006 | 24 | 0.060 |
Why?
| | Biopsy | 1 | 2009 | 1082 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2025 | 59 | 0.060 |
Why?
| | Caprylates | 1 | 2025 | 19 | 0.060 |
Why?
| | ROC Curve | 2 | 2019 | 618 | 0.060 |
Why?
| | Exons | 2 | 2019 | 364 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 615 | 0.050 |
Why?
| | Aged | 2 | 2023 | 26217 | 0.050 |
Why?
| | Equipment Design | 1 | 2026 | 525 | 0.050 |
Why?
| | Catheterization, Peripheral | 1 | 2006 | 120 | 0.050 |
Why?
| | Catheterization, Central Venous | 1 | 2006 | 123 | 0.050 |
Why?
| | Gene Regulatory Networks | 2 | 2019 | 318 | 0.050 |
Why?
| | Middle Aged | 3 | 2023 | 36309 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 206 | 0.050 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2023 | 38 | 0.050 |
Why?
| | Workflow | 1 | 2025 | 183 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 2602 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 2823 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 179 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 534 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1957 | 0.040 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 137 | 0.040 |
Why?
| | Antibodies | 1 | 2024 | 397 | 0.040 |
Why?
| | Bias | 1 | 2022 | 197 | 0.040 |
Why?
| | Replantation | 1 | 2021 | 32 | 0.040 |
Why?
| | Mice | 3 | 2025 | 18356 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2023 | 356 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 286 | 0.040 |
Why?
| | Data Accuracy | 1 | 2021 | 65 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2022 | 244 | 0.040 |
Why?
| | Social Class | 1 | 2022 | 264 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 229 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 228 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2019 | 4151 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 283 | 0.040 |
Why?
| | PPAR alpha | 1 | 2019 | 55 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5925 | 0.040 |
Why?
| | Carcinogens, Environmental | 1 | 2019 | 14 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 199 | 0.040 |
Why?
| | Cricetulus | 1 | 2019 | 118 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 172 | 0.040 |
Why?
| | CHO Cells | 1 | 2019 | 169 | 0.040 |
Why?
| | Chickens | 1 | 2019 | 179 | 0.040 |
Why?
| | Prevalence | 1 | 2026 | 2875 | 0.040 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2019 | 55 | 0.040 |
Why?
| | Micronucleus Tests | 1 | 2018 | 6 | 0.030 |
Why?
| | Therapeutic Equivalency | 1 | 2018 | 31 | 0.030 |
Why?
| | Anemia, Megaloblastic | 1 | 2018 | 9 | 0.030 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2018 | 8 | 0.030 |
Why?
| | Hyperplasia | 1 | 2018 | 177 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 209 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2019 | 293 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 39 | 0.030 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2019 | 214 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2021 | 732 | 0.030 |
Why?
| | Phytotherapy | 1 | 2018 | 74 | 0.030 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2017 | 4 | 0.030 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2017 | 3 | 0.030 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 1 | 2017 | 6 | 0.030 |
Why?
| | Activation, Metabolic | 1 | 2017 | 5 | 0.030 |
Why?
| | Barth Syndrome | 1 | 2017 | 9 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 197 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2019 | 242 | 0.030 |
Why?
| | Myotonic Dystrophy | 1 | 2017 | 9 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2017 | 76 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 196 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2017 | 36 | 0.030 |
Why?
| | Brazil | 1 | 2017 | 179 | 0.030 |
Why?
| | Infliximab | 1 | 2017 | 111 | 0.030 |
Why?
| | Hazardous Substances | 1 | 2016 | 16 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 65 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2017 | 141 | 0.030 |
Why?
| | Sample Size | 1 | 2017 | 121 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2018 | 238 | 0.030 |
Why?
| | Death | 1 | 2017 | 132 | 0.030 |
Why?
| | Folic Acid | 1 | 2018 | 198 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 73 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 690 | 0.030 |
Why?
| | Friedreich Ataxia | 1 | 2017 | 78 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 358 | 0.030 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 63 | 0.030 |
Why?
| | Pulsatile Flow | 1 | 2016 | 61 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 2017 | 132 | 0.030 |
Why?
| | Canada | 1 | 2017 | 432 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 381 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2017 | 536 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1662 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2015 | 133 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2022 | 1329 | 0.030 |
Why?
| | Catheters | 1 | 2015 | 74 | 0.030 |
Why?
| | Colonoscopy | 1 | 2017 | 264 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 94 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2014 | 17 | 0.030 |
Why?
| | Kidney Tubules, Proximal | 1 | 2015 | 129 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 2064 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 31 | 0.030 |
Why?
| | Gene Library | 1 | 2014 | 122 | 0.030 |
Why?
| | Tissue Donors | 1 | 2017 | 420 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 337 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 1165 | 0.020 |
Why?
| | Organ Specificity | 1 | 2014 | 309 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2021 | 3634 | 0.020 |
Why?
| | Area Under Curve | 1 | 2014 | 332 | 0.020 |
Why?
| | Glucuronosyltransferase | 1 | 2013 | 18 | 0.020 |
Why?
| | Electrocardiography | 1 | 2017 | 668 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1247 | 0.020 |
Why?
| | E2F1 Transcription Factor | 1 | 2013 | 68 | 0.020 |
Why?
| | Radiation Effects | 1 | 2012 | 7 | 0.020 |
Why?
| | Genetic Variation | 1 | 2018 | 977 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2013 | 194 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2014 | 248 | 0.020 |
Why?
| | Erythrocytes | 1 | 2018 | 749 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1036 | 0.020 |
Why?
| | Models, Molecular | 1 | 2017 | 1599 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 515 | 0.020 |
Why?
| | Tobacco Products | 1 | 2012 | 84 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2013 | 166 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 177 | 0.020 |
Why?
| | Testosterone | 1 | 2015 | 416 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3551 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2933 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2015 | 756 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3211 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2013 | 373 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1197 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4116 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1450 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2007 | 115 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2007 | 124 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 574 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 505 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 489 | 0.010 |
Why?
| | Subclavian Vein | 1 | 2006 | 15 | 0.010 |
Why?
| | Pregnancy | 1 | 2017 | 7216 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 896 | 0.010 |
Why?
| | Base Sequence | 1 | 2007 | 2171 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 3170 | 0.010 |
Why?
|
|
Auerbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|